Tag: papulopustular rosacea

Minocycline Extended-Release Comparison with Doxycycline for the Treatment of Rosacea: A Randomized, Head-to-Head, Clinical Trial

J Clin Aesthet Dermatol. 2021;14(12):16–23. by Anthanasios Tsianakas, MD; Thomas Pieber, MD; Hilary Baldwin, MD; Franz Feichtner, PhD; Shanavas Alikunju, PhD; Anirudh Gautam, MPharm; Srinivas Shenoy, MD; Preeti Singh, MD; and Srinivas Sidgiddi, MD Dr. Tsianakas is with the Department of Dermatology at Fachklinik Bad Bentheim in Bad Bentheim, Germany. Dr. Pieber is with the


Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

J Clin Aesthet Dermatol. 2021;14(3):E53–E57.  by Terry M. Jones, MD, and Iain Stuart, PhD Dr. Jones is with J&S Studies Inc., in College Station, Texas. Dr. Stuart is with VYNE Therapeutics Inc., in Bridgewater, New Jersey.  FUNDING: This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc. DISCLOSURES: Dr.


Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

J Clin Aesthet Dermatol. 2020;13(11):44–49 by Linda Stein Gold, MD; James Q. Del Rosso, DO; Leon Kircik, MD; Neal D. Bhatia, MD; Deirdre Hooper, MD; Walter Nahm, MD, PhD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Del Rosso is the Research Director at JDR